Residency · Residency · Endocrinology

Thyroid Physiology and Function Testing

Thyroid Gland Anatomy and Embryology

Anatomy

The thyroid gland is a bilobed structure connected by a central isthmus, situated anterior to the trachea at the level of the C5 to T1 vertebrae. In adults, it weighs between 15 and 25 grams and is one of the most highly vascularized organs in the body, with a blood flow of 4 to 6 mL per gram per minute. A pyramidal lobe, representing a remnant of the thyroglossal duct, is present in approximately 50% of individuals and extends superiorly from the isthmus.

The surgical anatomy of the thyroid gland is defined by its critical relationship to the recurrent laryngeal nerves, which run in the tracheoesophageal groove posterior to the thyroid lobes and are vulnerable to injury during thyroidectomy. The external branch of the superior laryngeal nerve, which innervates the cricothyroid muscle responsible for voice pitch modulation, is similarly at risk during dissection of the superior pole. The blood supply derives from the superior thyroid artery (a branch of the external carotid), the inferior thyroid artery (a branch of the thyrocervical trunk), and in approximately 3% of individuals, a thyroid ima artery arising from the brachiocephalic trunk or the aortic arch.

Embryology

The thyroid gland originates from the endoderm of the foramen cecum at the base of the tongue during weeks 3 to 4 of embryonic development. The primordial thyroid anlage descends through the neck via the thyroglossal duct, reaching its final pretracheal position by approximately week 7. The thyroglossal duct normally obliterates during development, but remnants may persist and give rise to thyroglossal duct cysts, the most common midline neck mass in children.

The parafollicular C cells have a distinct embryological origin, deriving from neural crest cells that migrate through the ultimobranchial body of the fourth pharyngeal pouch. These cells produce calcitonin and are the cell of origin for medullary thyroid carcinoma. Lingual thyroid represents a failure of normal descent, leaving thyroid tissue at the base of the tongue that may be the individual's only functioning thyroid tissue. Thyroid dysgenesis, encompassing agenesis, ectopy, and hypoplasia, accounts for approximately 85% of congenital hypothyroidism.

Histology

The functional unit of the thyroid gland is the thyroid follicle, a spherical structure composed of a single layer of follicular epithelial cells surrounding a central lumen filled with colloid. The colloid is composed primarily of thyroglobulin in its iodinated form, representing the stored form of thyroid hormone precursor. Follicular cells exhibit clear polarity, with the apical surface facing the colloid and the basolateral surface facing the capillary network. This polarity is essential for the vectorial transport of iodide and the secretion of thyroid hormones. C cells are scattered between follicles and within the follicular basement membrane, constituting approximately 0.1% of total thyroid mass.

Thyroid Hormone Synthesis

Iodine Metabolism

Iodine is an essential trace element required for thyroid hormone synthesis. The recommended daily intake is 150 mcg for adults and 250 mcg during pregnancy and lactation. Dietary sources include iodized salt, dairy products, seafood, seaweed, and, in some countries, bread. Population iodine status is assessed by urinary iodine concentration (UIC), with a median value above 100 mcg/L indicating sufficiency. Iodine excess, defined as intake exceeding 1100 mcg per day in adults, can paradoxically cause either hypothyroidism or hyperthyroidism depending on the underlying thyroid status and the mechanisms discussed below.

Steps of Hormone Synthesis

Thyroid hormone synthesis proceeds through an elegant sequence of six major steps. The process begins with iodide trapping, in which the sodium-iodide symporter (NIS) on the basolateral membrane of follicular cells actively transports iodide against a 20- to 40-fold concentration gradient. NIS expression is upregulated by TSH and can be competitively inhibited by perchlorate, pertechnetate, and thiocyanate. Iodide is then transported across the cell to the apical surface by pendrin (encoded by the SLC26A4 gene) and other channels; mutations in pendrin cause Pendred syndrome, characterized by goiter and sensorineural deafness.

At the apical surface, thyroid peroxidase (TPO) catalyzes the oxidation of iodide to reactive iodine using hydrogen peroxide generated by the dual oxidase system (DUOX2/DUOXA2). The reactive iodine is then incorporated into tyrosine residues on thyroglobulin in the colloid through a process termed organification, forming monoiodotyrosine (MIT) and diiodotyrosine (DIT). TPO then catalyzes the coupling of these iodotyrosines: coupling of two DIT molecules produces T4 (thyroxine), while coupling of MIT with DIT produces T3 (triiodothyronine). The T4-to-T3 ratio on thyroglobulin is approximately 15:1, reflecting the predominant production of T4.

Iodinated thyroglobulin is stored as colloid within the follicular lumen, providing a reservoir of approximately 2 to 3 months of hormone supply. Upon TSH stimulation, colloid is internalized by pinocytosis and undergoes lysosomal proteolysis, releasing T4 and T3 into the circulation. The MIT and DIT residues that are not coupled are deiodinated intracellularly by dehalogenase (DEHAL1), allowing the iodine to be recycled for further hormone synthesis.

Wolff-Chaikoff Effect

The Wolff-Chaikoff effect is a critical autoregulatory mechanism in which acute exposure to excess iodide transiently blocks organification by inhibiting TPO activity, thereby decreasing thyroid hormone synthesis. Under normal circumstances, the gland escapes from this effect within 24 to 48 hours through downregulation of NIS, which reduces intracellular iodide to levels that no longer inhibit organification. However, thyroid glands with underlying pathology, including those affected by Hashimoto thyroiditis, those previously treated with radioactive iodine, and the fetal thyroid, may fail to escape, resulting in iodine-induced hypothyroidism.

The converse phenomenon, the Jod-Basedow effect, refers to iodine-induced hyperthyroidism occurring in thyroid glands harboring autonomous nodules, such as in toxic multinodular goiter or Graves disease. This is particularly observed in iodine-deficient regions following introduction of iodine supplementation or after administration of iodine-containing contrast agents or amiodarone.

<image>A step-by-step diagram of thyroid hormone synthesis within a thyroid follicular cell. Show the follicular cell with apical surface facing the colloid and basolateral surface facing a capillary. Label: (1) NIS on basolateral membrane transporting iodide with sodium, (2) pendrin on apical membrane transporting iodide to colloid, (3) TPO on apical surface oxidizing iodide using H2O2 from DUOX2, (4) organification of iodide onto thyroglobulin tyrosine residues forming MIT and DIT, (5) coupling reactions DIT+DIT forming T4 and MIT+DIT forming T3, (6) pinocytosis of colloid, (7) lysosomal digestion releasing T4 and T3, (8) T4 and T3 secretion into capillary. Show TSH receptor on basolateral membrane with Gs-cAMP pathway. Use arrows and numbered steps in clean medical illustration style.</image>

Thyroid Hormone Transport and Metabolism

Serum Transport Proteins

More than 99.9% of circulating thyroid hormones are bound to plasma proteins, with only the free (unbound) fractions being biologically active. | Transport Protein | % T4 Carried | % T3 Carried | Key Characteristics | Conditions Increasing Levels | Conditions Decreasing Levels |

Three major transport proteins carry thyroid hormones in the circulation. Thyroxine-binding globulin (TBG), a 54-kDa glycoprotein synthesized in the liver, carries approximately 75% of both T4 and T3. Transthyretin (TTR, also known as prealbumin) carries approximately 15% of circulating T4 and also serves as a transport protein for retinol. Albumin carries approximately 10%, with low affinity but high capacity.

The free fractions are remarkably small: approximately 0.02% of total T4 and 0.3% of total T3 circulate in the unbound state. This distinction between total and free hormone levels is of paramount clinical importance because many physiological and pathological conditions alter binding protein levels, thereby changing total hormone concentrations without affecting the biologically relevant free fractions. Conditions that increase TBG include pregnancy, estrogen or oral contraceptive use, hepatitis, opioid use, tamoxifen therapy, and genetic TBG excess. Conditions that decrease TBG include androgen use, glucocorticoids, nephrotic syndrome, severe illness, genetic TBG deficiency, and liver failure.

Familial dysalbuminemic hyperthyroxinemia (FDH) is an important diagnostic pitfall caused by an albumin variant with increased T4 affinity. This condition produces falsely elevated total T4 and, in some assay platforms (particularly analog methods), falsely elevated free T4, potentially leading to an erroneous diagnosis of hyperthyroidism. Free T4 measured by equilibrium dialysis, the gold standard method, will be normal.

Deiodinase System

The deiodinase enzyme system is responsible for the peripheral conversion and inactivation of thyroid hormones and determines the intracellular thyroid hormone milieu in target tissues. | Deiodinase | Tissue Expression | Reaction | Clinical Relevance |

Three deiodinases have been characterized. Type 1 deiodinase (D1), expressed in liver, kidney, and thyroid, catalyzes both outer-ring deiodination of T4 to T3 and inner-ring deiodination of T4 to reverse T3 (rT3). D1 is notably inhibited by propylthiouracil (PTU) but not by methimazole, and contributes to the circulating T3 pool. Type 2 deiodinase (D2), expressed in brain, pituitary, brown adipose tissue, skeletal muscle, and placenta, converts T4 to T3 locally and is critical for maintaining intracellular T3 concentrations in the brain and pituitary. D2 is upregulated in hypothyroidism, providing a compensatory mechanism. Type 3 deiodinase (D3), expressed in brain, placenta, and skin, inactivates T4 to rT3 and T3 to T2, serving a protective role in the fetus and during critical illness.

An essential physiological principle is that approximately 80% of circulating T3 is produced by peripheral deiodination of T4, primarily by D1 and D2, with only 20% coming from direct thyroid secretion. T3 is 3 to 5 times more potent than T4 at the thyroid hormone receptor, and T4 is best conceptualized as a prohormone that serves as the substrate for tissue-specific T3 generation.

Thyroid Hormone Action

Thyroid hormones exert their classical genomic effects through nuclear thyroid hormone receptors. T3 enters the nucleus and binds to thyroid hormone receptors, which exist as two major isoforms with distinct tissue distributions. TR-alpha1, expressed predominantly in heart, bone, brain, and skeletal muscle, mediates the chronotropic and inotropic cardiac effects of thyroid hormone. TR-beta1, expressed in liver and kidney, mediates effects on cholesterol metabolism and other hepatic functions. TR-beta2, expressed specifically in the hypothalamus and pituitary, is the receptor isoform responsible for the negative feedback suppression of TRH and TSH by thyroid hormones.

At the molecular level, thyroid hormone receptors bind to thyroid response elements (TREs) in target gene promoters as heterodimers with the retinoid X receptor (RXR), recruiting coactivators in the presence of T3 and corepressors in its absence. In addition to these genomic actions, thyroid hormones exert rapid non-genomic effects on membrane ion channels, mitochondrial function, and the cytoskeleton.

TSH and the HPT Axis Feedback

TSH Physiology

TSH is a glycoprotein hormone composed of an alpha subunit (shared with LH, FSH, and hCG) and a unique beta subunit that confers biological specificity. The normal reference range is approximately 0.4 to 4.0 mIU/L, though this is assay-dependent and the appropriate upper limit remains debated. TSH secretion follows a circadian rhythm, with a nadir in the late afternoon and a nocturnal surge that peaks around midnight, with an amplitude of 50 to 100% above the daytime nadir.

The defining feature of TSH regulation is the log-linear inverse relationship with free T4: a 2-fold change in free T4 concentration produces an approximately 100-fold change in TSH. This amplified sensitivity makes TSH the most sensitive indicator of primary thyroid dysfunction and explains why TSH changes are detected long before free T4 leaves the reference range in evolving thyroid disease.

The TSH receptor on thyroid follicular cells is a Gs-coupled G-protein-coupled receptor that activates the cAMP-PKA signaling cascade, stimulating all aspects of thyroid hormone synthesis, from iodide uptake through hormone secretion, as well as thyroid gland growth. The TSH receptor is also the target of autoantibodies in autoimmune thyroid disease: stimulating antibodies in Graves disease, blocking antibodies in atrophic thyroiditis, and neutral antibodies with uncertain clinical significance.

Regulation of TSH

TSH secretion is stimulated by TRH, cold exposure, dopamine antagonists, and melatonin. It is inhibited by thyroid hormones (T3 acting at the pituitary through TR-beta2, derived from local D2-mediated conversion of T4), somatostatin, dopamine, glucocorticoids, and severe illness (the euthyroid sick syndrome). The primary negative feedback signal at the pituitary is T3 generated locally within thyrotrophs by D2-mediated conversion of circulating T4, rather than circulating T3 itself.

Thyroid Function Tests

TSH

TSH is the most sensitive screening test for primary thyroid disease, a consequence of the log-linear amplification of the TSH-free T4 relationship. Third-generation TSH assays, with a functional sensitivity of 0.01 to 0.02 mIU/L, can reliably distinguish normal from suppressed values, which is essential for the diagnosis and monitoring of hyperthyroidism.

However, TSH has important limitations. It is not reliable for diagnosing or monitoring central hypothyroidism, in which TSH may be low, normal, or even mildly elevated due to the secretion of biologically inactive TSH glycosylation variants. Several conditions can produce falsely elevated TSH results, including heterophilic antibodies (human anti-mouse antibodies or HAMA), macro-TSH (IgG-TSH complexes with prolonged half-life), TSH-secreting pituitary adenomas, thyroid hormone resistance syndromes, recovery from nonthyroidal illness, and adrenal insufficiency. Falsely low TSH may be observed in severe nonthyroidal illness, dopamine infusion, glucocorticoid excess, and during the first trimester of pregnancy (when hCG cross-reacts at the TSH receptor, producing physiological thyrotoxicosis).

Free T4 and Free T3

Free T4 and free T3 are typically measured by immunoassay using either analog or two-step methods, with equilibrium dialysis serving as the gold standard reference method. Immunoassay platforms are subject to several important interferences: binding protein abnormalities can affect results, heterophilic antibodies may cause falsely elevated values, and biotin interference in streptavidin-biotin-based assays is an increasingly recognized problem. Biotin supplementation, even at doses of 5 to 10 mg daily as commonly found in hair and nail supplements, can cause falsely low TSH and falsely high free T4 and T3 results, producing a pattern that mimics Graves disease.

Free T4, with a reference range of approximately 0.8 to 1.8 ng/dL (assay-dependent), is the primary confirmatory test when TSH is abnormal. Free T3 measurement is useful when T3-thyrotoxicosis is suspected (normal free T4 but clinically thyrotoxic) but has limited utility in the evaluation of hypothyroidism.

Total T4 and Total T3

Total T4 and total T3 measurements reflect both bound and free hormone and are therefore affected by changes in binding protein concentrations, making them less useful as standalone tests. However, total T3 retains diagnostic value in certain situations: a markedly elevated total T3 with a T3-to-T4 ratio exceeding 20:1 (ng/dL:mcg/dL) is suggestive of Graves disease, which characteristically produces proportionally more T3 than other causes of thyrotoxicosis.

Thyroglobulin (Tg)

Thyroglobulin is produced exclusively by thyroid follicular cells, both normal and malignant, making it an exquisitely specific tumor marker for differentiated thyroid cancer following thyroidectomy. In the intact thyroid, thyroglobulin is elevated in destructive thyroiditis, Graves disease, and goiter, limiting its diagnostic utility in these settings. Anti-thyroglobulin antibodies (TgAb), present in 15 to 25% of patients with differentiated thyroid cancer, interfere with thyroglobulin immunoassays, typically producing falsely low values. In these patients, the TgAb trend itself is followed as a surrogate tumor marker, with declining titers suggesting disease regression. Thyroglobulin measurement by liquid chromatography-tandem mass spectrometry (LC-MS/MS) is not affected by TgAb interference but is less sensitive than immunometric assays.

Thyroid Antibodies

Anti-TPO antibodies are the most sensitive serological marker of autoimmune thyroid disease, present in more than 90% of patients with Hashimoto thyroiditis and approximately 75% of those with Graves disease. In the setting of subclinical hypothyroidism, positive anti-TPO antibodies predict progression to overt hypothyroidism. Titers correlate with the degree of lymphocytic infiltration of the thyroid. Anti-thyroglobulin antibodies are present in 60 to 80% of Hashimoto patients but are less specific. TSH receptor antibodies (TRAb) can be measured as thyroid-stimulating immunoglobulins (TSI) or thyrotropin-binding inhibitory immunoglobulins (TBII) and are diagnostic for Graves disease. When elevated in the third trimester of pregnancy, they predict the risk of fetal and neonatal hyperthyroidism through transplacental passage.

Radioactive Iodine Uptake (RAIU)

The radioactive iodine uptake test measures the percentage of administered I-123 (or I-131) taken up by the thyroid at 4 to 6 hours and at 24 hours. Normal 24-hour uptake ranges from 10 to 30%, varying by geographic iodine intake. Elevated uptake is seen in Graves disease (diffuse uptake), toxic adenoma (focal uptake), and toxic multinodular goiter (patchy uptake). Low or absent uptake is the hallmark of thyroiditis (subacute, painless, or postpartum), exogenous thyroid hormone use, iodine excess, and struma ovarii. The RAIU test is the single most discriminating study for differentiating the causes of thyrotoxicosis and is contraindicated only in pregnancy and breastfeeding.

<image>A diagnostic algorithm for evaluating thyroid function test results. Start with TSH result. Branch 1: Low TSH - check free T4 and free T3. If both elevated: overt hyperthyroidism - then branch to RAIU (high = Graves/toxic nodule; low = thyroiditis/exogenous). If free T4 normal, free T3 elevated: T3-thyrotoxicosis. If both normal: subclinical hyperthyroidism. Branch 2: Normal TSH - euthyroid (or central thyroid disorder if clinical suspicion, check free T4). Branch 3: Elevated TSH - check free T4. If low: overt hypothyroidism (check TPO antibodies). If normal: subclinical hypothyroidism. Add a side branch for elevated TSH with elevated free T4: TSH-secreting adenoma vs thyroid hormone resistance. Use flowchart format with decision diamonds and color-coded outcomes.</image>

Thyroid Uptake Scan Patterns

The patterns observed on thyroid scintigraphy provide crucial diagnostic information. Graves disease produces diffuse, homogeneous uptake with elevated RAIU. Toxic multinodular goiter shows heterogeneous, patchy uptake with hot and cold areas reflecting the mixture of autonomous and non-autonomous tissue. A toxic adenoma presents as a single hot nodule with suppression of the surrounding gland due to TSH suppression from autonomous hormone production. Subacute thyroiditis demonstrates globally decreased or absent uptake reflecting inflammation-mediated destruction rather than active hormone synthesis. Factitious thyrotoxicosis also shows absent uptake, but is distinguished by low thyroglobulin levels indicating an exogenous hormone source.

Nonthyroidal Illness Syndrome (Euthyroid Sick Syndrome)

Pathophysiology

Nonthyroidal illness syndrome (NTIS), also termed euthyroid sick syndrome, represents an adaptive response of the thyroid axis to acute or chronic illness. The changes are driven by cytokine-mediated effects (IL-1, IL-6, TNF-alpha) that alter thyroid hormone metabolism and the hypothalamic-pituitary-thyroid axis set point. At the enzymatic level, D1 activity is reduced while D3 activity is increased, shifting thyroid hormone metabolism away from active T3 production and toward the generation of inactive metabolites (reverse T3 and T2). Simultaneously, the central set point is altered, with decreased TSH pulse amplitude, and binding protein levels decline, particularly during severe illness.

Laboratory Patterns

The thyroid function test abnormalities in NTIS follow a predictable pattern that correlates with illness severity. In mild illness, T3 is low while T4 and TSH remain normal, a pattern termed the "low T3 syndrome." As illness severity progresses to moderate, both T3 and T4 fall to the low-normal range, and TSH begins to decline. In severe or critical illness, T3 and T4 are frankly low with a low TSH, a pattern that closely mimics central hypothyroidism and carries a poor prognosis, with an inverse correlation between T4 levels and ICU mortality. During the recovery phase, TSH may transiently rise above the normal range, sometimes reaching 10 to 20 mIU/L, before normalizing.

Clinical Approach

The most important clinical principle regarding NTIS is to avoid checking thyroid function tests in acutely ill patients unless there is a strong clinical suspicion of preexisting thyroid disease. If testing has been obtained, the results should be repeated 4 to 6 weeks after recovery before any thyroid diagnosis is made or treatment initiated. Multiple randomized controlled trials, including the THYROID and TRISS trials, have demonstrated that thyroid hormone replacement in euthyroid sick syndrome provides no clinical benefit. Reverse T3, while elevated in NTIS and low in true hypothyroidism, is of limited practical clinical utility in distinguishing the two conditions.

Special Populations

Pregnancy

Pregnancy induces several important changes in thyroid physiology that must be accounted for in test interpretation. Human chorionic gonadotropin (hCG), which is structurally similar to TSH, stimulates the TSH receptor, causing physiological thyrotoxicosis that peaks at 10 to 12 weeks of gestation and may manifest as gestational thyrotoxicosis. Consequently, TSH reference ranges are lower during pregnancy: approximately 0.1 to 2.5 mIU/L in the first trimester, 0.2 to 3.0 in the second, and 0.3 to 3.5 in the third, though the 2017 ATA guidelines recommend using assay-specific and population-specific reference ranges when available.

TBG levels increase 2- to 3-fold during pregnancy, driven by estrogen-stimulated hepatic synthesis and reduced TBG clearance due to increased sialylation. This produces proportional increases in total T4 and T3, while free hormone levels should remain normal. Maternal T4 crosses the placenta and is essential for fetal brain development, particularly during the first trimester before the fetal thyroid begins functioning at 10 to 12 weeks. The fetal HPT axis becomes functionally independent by 18 to 20 weeks of gestation.

Aging

The interpretation of thyroid function tests in elderly populations requires special consideration. Data from NHANES III and other population studies demonstrate that the TSH distribution shifts rightward with age, with the 97.5th percentile reaching 5 to 7 mIU/L in octogenarians. This observation, combined with data suggesting that higher TSH levels may be associated with longevity in the elderly, has raised questions about whether mild TSH elevation represents a normal age-related adaptation rather than pathology. The TRUST trial provided strong evidence against routine treatment of subclinical hypothyroidism (TSH 4.6 to 19.9 mIU/L) in patients aged 65 years and older, showing no benefit in symptoms or quality of life.

<image>A comprehensive reference table showing thyroid function test patterns in different clinical conditions. Create a grid with conditions as rows: Normal, Primary hypothyroidism, Subclinical hypothyroidism, Primary hyperthyroidism, Subclinical hyperthyroidism, Central hypothyroidism, TSH-secreting adenoma, Thyroid hormone resistance, Nonthyroidal illness (mild/severe), Pregnancy 1st trimester, TBG excess, and Biotin interference. Columns: TSH, Free T4, Free T3, Total T4, RAIU. Use arrows (up, down, normal) with specific directional indicators. Color code: red for abnormal high, blue for abnormal low, green for normal. Include footnotes for important caveats.</image>

Key Clinical Pearls

• Biotin supplementation (even 5-10 mg/day, commonly found in hair/nail supplements) can cause significant interference in streptavidin-biotin-based immunoassays; pattern mimics Graves disease (low TSH, high free T4/T3); stop biotin 48-72 hours before testing
• In central hypothyroidism, TSH is unreliable for both diagnosis and monitoring; always follow free T4 (target upper half of normal range)
• The log-linear TSH-free T4 relationship means a patient with TSH 10 mIU/L and low-normal free T4 has more thyroid dysfunction than the free T4 alone suggests
• Low RAIU with thyrotoxicosis has a limited differential: thyroiditis (subacute, painless, postpartum), exogenous thyroid hormone, iodine excess, struma ovarii; RAIU is the single most discriminating test
• During nonthyroidal illness recovery, transient TSH elevation (up to 10-20 mIU/L) should not trigger levothyroxine therapy; repeat in 4-6 weeks
• Anti-TPO antibodies in a euthyroid patient predict ~4.3% annual risk of developing hypothyroidism (Wickham survey); higher risk if TSH already mildly elevated

References

1. Braverman LE, Cooper DS, Kopp PA. "Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text." 11th edition. Lippincott Williams & Wilkins, 2020.
2. Alexander EK, et al. "2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum." Thyroid. 2017;27(3):315-389.
3. Peeters RP. "Nonthyroidal Illness: To Treat or Not to Treat?" Ann Intern Med. 2019;171(7):516-517.
4. Stott DJ, et al. "Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism (TRUST)." N Engl J Med. 2017;376(26):2534-2544.
5. Baloch Z, et al. "Laboratory Medicine Practice Guidelines: Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease." Thyroid. 2003;13(1):3-126.

Read this lecture as Markdown